Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q1 2021 · 10-Q
Revenue$11.12M$11.12M+26.9% vs Q1 2020 Net Income-$14.67M-$14.67MN/M vs Q1 2020 EPS Diluted-$0.41-$0.41N/M vs Q1 2020 Operating Income-$8,525,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
Free Cash Flowderived-$14,200,000N/M Margins · derivedOperating margin-76.6%+81.5 pt vs Q1 2020
Net margin-131.9%+56.7 pt vs Q1 2020
ended Mar 31, 2021 · filed May 4, 2021 · 34 d after period end